80 related articles for article (PubMed ID: 22987962)
1. Going beyond EGFR.
Zimmermann S; Peters S
Ann Oncol; 2012 Sep; 23 Suppl 10():x197-203. PubMed ID: 22987962
[TBL] [Abstract][Full Text] [Related]
2. The impact of genomic changes on treatment of lung cancer.
Cardarella S; Johnson BE
Am J Respir Crit Care Med; 2013 Oct; 188(7):770-5. PubMed ID: 23841470
[TBL] [Abstract][Full Text] [Related]
3. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
[TBL] [Abstract][Full Text] [Related]
5. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.
Dang AH; Tran VU; Tran TT; Thi Pham HA; Le DT; Nguyen L; Nguyen NV; Thi Nguyen TH; Nguyen CV; Le HT; Thi Nguyen ML; Le VT; Nguyen PH; Vo BT; Thi Dao HT; Nguyen LT; Van Nguyen TC; Bui QN; Nguyen LH; Nguyen NH; Thi Nguyen QT; Le TX; Do TT; Dinh KT; Do HN; Phan MD; Nguyen HN; Tran LS; Giang H
Sci Rep; 2020 Feb; 10(1):2707. PubMed ID: 32066856
[TBL] [Abstract][Full Text] [Related]
6. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
Ishida M; Iwasaku M; Doi T; Ishikawa T; Tachibana Y; Sawada R; Ogura Y; Kawachi H; Katayama Y; Nishioka N; Morimoto K; Tokuda S; Yamada T; Takayama K
Cancer Sci; 2024 May; 115(5):1656-1664. PubMed ID: 38450844
[TBL] [Abstract][Full Text] [Related]
7. Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.
Marchal M; Leroy V; Behal H; Dansin E; Paris N; Bordier S; Humez S; Escande F; Gauvain C; Cortot AB
Target Oncol; 2023 Nov; 18(6):927-939. PubMed ID: 37921939
[TBL] [Abstract][Full Text] [Related]
8. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
Kim EK; Kim KA; Lee CY; Shim HS
PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract][Full Text] [Related]
10. [Advances of molecular subtype and targeted therapy of lung cancer].
Shao L; Song Z; Zhang Y; Su D
Zhongguo Fei Ai Za Zhi; 2012 Sep; 15(9):545-52. PubMed ID: 22989458
[TBL] [Abstract][Full Text] [Related]
11. Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.
Abdel Karim N; Kelly K
Oncologist; 2019 Sep; 24(9):1270-1284. PubMed ID: 30914465
[TBL] [Abstract][Full Text] [Related]
12. Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell Lung Cancer.
Kanasaki H; Ozawa Y; Nakamura N; Nagasaki K; Matsuyama W; Akahori D; Niwa M; Ogasawara T; Sato J
Anticancer Res; 2024 Feb; 44(2):723-730. PubMed ID: 38307579
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.
Rothschild SI
Cancers (Basel); 2015 May; 7(2):930-49. PubMed ID: 26018876
[TBL] [Abstract][Full Text] [Related]
14. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.
Best MG; Sol N; Kooi I; Tannous J; Westerman BA; Rustenburg F; Schellen P; Verschueren H; Post E; Koster J; Ylstra B; Ameziane N; Dorsman J; Smit EF; Verheul HM; Noske DP; Reijneveld JC; Nilsson RJA; Tannous BA; Wesseling P; Wurdinger T
Cancer Cell; 2015 Nov; 28(5):666-676. PubMed ID: 26525104
[TBL] [Abstract][Full Text] [Related]
15. Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes.
Leung KK; Wilson GM; Kirkemo LL; Riley NM; Coon JJ; Wells JA
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):7764-7775. PubMed ID: 32205440
[TBL] [Abstract][Full Text] [Related]
16. The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.
Wumener X; Zhang Y; Zang Z; Du F; Ye X; Zhang M; Liu M; Zhao J; Sun T; Liang Y
BMC Pulm Med; 2024 May; 24(1):227. PubMed ID: 38730287
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Chemical Constituents of Miao Ethnomedicine Heiguteng Zhuifeng Huoluo Capsule (HZFC) and the Discovery of Active Substances in the Treatment of Rheumatoid Arthritis.
Mu KL; Li L; Chen Y; Zhang MJ; He TL; Li KM; Liu YC; Liu G
ACS Omega; 2024 Mar; 9(9):10860-10874. PubMed ID: 38463300
[TBL] [Abstract][Full Text] [Related]
18. Screening of potential biomarkers and their predictive value in early stage non-small cell lung cancer: a bioinformatics analysis.
Tu H; Wu M; Huang W; Wang L
Transl Lung Cancer Res; 2019 Dec; 8(6):797-807. PubMed ID: 32010558
[TBL] [Abstract][Full Text] [Related]
19. Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma.
Dong Y; Li Y; Jin B; Zhang J; Shao J; Peng H; Tu S; Han B
Oncotarget; 2017 Oct; 8(47):82244-82255. PubMed ID: 29137260
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.
Delaney C; Frank S; Huang RS
Chin J Cancer; 2015 Apr; 34(4):149-60. PubMed ID: 25962919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
